PERTH: MyFiziq Limited has executed definitive agreements with Biomorphik Pty Ltd, an Australian based behavioural change and technology company, a news release said.

Biomorphik has developed a medical health and wellness platform, that is the bridge between medical and health/wellness, with the aim of reducing health costs at all levels of society from the individual, to healthcare and insurance systems, and governments.

Under the commercial terms of the definitive agreements, Biomorphik and MyFiziq have commenced working together to build and release an initial product by the 10th November 2020 using MyFiziq’s new Body Scan On Demand product which comprises a set of standalone iOS and Android applications, branded in Biomorphik colours, linked to Biomorphik’s iOS and Android applications via cross app deep linking.

In parallel with the accelerated time to market integration, the parties are also working on a full integration of the MyFiziq SDKs into the new platform that Biomorphik is developing. With a target release date ofQ1 2021, the new MyFiziq integrated Biomorphik platform will also include multi-language versions to target specific countries in Asia.

Body Scan On Demand is a new product provided by MyFiziq that utilises cross app linking to allow partner applications to invoke MyFiziq’s scanning technology without having to directly integrate SDKs into their own application.

Partner applications can simply use either an Apple Universal Link on iOS, or a Deep Link on Android, to route their users to MyFiziq’s On Demand service.

Vlado Bosanac, Chief Executive Officer of MyFiziq, said: “Biomorphik is our first partner to take advantage of our newly developed Body Scan On Demand cross linked iOS and Android applications, which we have built to get integrated products to market quicker, in turn, enabling swifter user revenue generation for MyFiziq and our partners.

“As previously announced to the ASX in early August, Biomorphik originally confirmed a January 2021 MyFiziq integrated release. However, since then, Biomorphik has experienced a surge of new business interest in Asia due to the COVID-19 pandemic. Due to the surge in demand, we are now working with Nathaniel and his team to release the initial product to market by 10^th November 2020, 3 months earlier than originally advised to the ASX. In conjunction with the express to market product, we are working with Nathaniel’s marketing team to build out a joint marketing campaign to drive users throughout Asia to the Biomorphik platform. The joint marketing campaign will focus on both user acquisition as user engagement and is targeted to commence in-line with the November 2020 release.

“Biomorphik has undertaken a user target of 100,000 active users in the first 12 months and MyFiziq is happy to play a role in achieving this target with a joint marketing campaign.”

Nathaniel Peek, Chief Executive Officer of Biomorphik said: “Biomorphik has had a surge of interest in our product offering from governments and large corporations across Asia as a result of the current pandemic, with people, corporations and governments better understanding the value of a healthy lifestyle and its impacts on individuals, families, business, and economies.

“By implementing the MyFiziq On Demand and full integrations in parallel, MyFiziq is assisting Biomorphik in keeping pace with the surge in demand for our products, whilst at the same time enabling us to develop our complete solution using MyFiziq’s SDK’s that is unique to our brand, user experience and value propositions. I believe this early release will not only assist us in meeting the user target of 100,000 active users, but it will also be highly visible in attracting a larger audience for both Biomorphik and MyFiziq. Our partnership with MyFiziq will allow us to scale endlessly as we extend our product range into new markets worldwide.”

www.myfiziq.com